Press releases

Appointment will fill a vacancy that will result from the Board's decision to increase the number of directors comprising the Board from ten to eleven.

Represents important milestone toward making WATCHMAN device available to patients with atrial fibrillation.

Data presented at NANS 2013 show highly significant reduction in pain and high trial therapy success rate in the treatment of chronic pain.

Companies will collaborate to provide promotional support for stent system in U.S. hospitals

Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug...

Boston Scientific will participate in the healthcare conference on December 3 in New York. Learn how to watch the webcast or replay.

Brings more than 20 years of financial and healthcare industry experience, including extensive knowledge of the medtech industry.

Proprietary shaft design enables better control in hard-to-navigate vessels

First system to selectively stimulate targeted areas of the brain to manage symptoms of debilitating disease

Patients In Germany receive new transcatheter aortic valve implantation devices specially designed for total control and accurate deployment.

Boston Scientific will participate in the healthcare conference on November 12 in Scottsdale, AZ. Learn how to watch the webcast or replay.

Advances Boston Scientific's ability to more comprehensively serve the rapidly expanding global EP market.

New data demonstrate successful deployment in all 120 patients with no severe paravalvular regurgitation at 30 days

Boston Scientific will participate in the healthcare conference on November 12. Learn how to watch the webcast or replay.

REDUCE-HTN data presented today at TCT demonstrate excellent safety profile.

Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful...

Transcatheter Aortic Valve Replacement (TAVR) device offers precise positioning and placement, offering physicians unprecedented control.

Jeffrey Capello to transition out of CFO role at year-end

"We accelerated our operational performance in the quarter while enhancing our ability to deliver meaningful innovation,” said CEO Mike Mahoney.

Revolutionary procedure clinically proven to provide long term reduction of asthma exacerbations

Award recognizes innovative S-ICD® System, the world's first and only subcutaneous implantable defibrillator.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ending September 30, 2013. Learn how to tune in.

MAJESTIC trial to study self-expanding DES System designed to treat superficial femoral artery (SFA) lesions.

University of Pittsburgh independent study of contemporary heart failure devices highlights industry-leading Boston Scientific battery longevity.

Re-ROUTE trial data presented at VIVA 2013 late-breaking session